A female patient, 42 years of age, with type 2 diabetes, is overweight with a history of vaginal yeast infections with elevated glucose levels. Wanting to better manage her diabetes and lose some weight, the commercials about SGLT-2 inhibitors caught her attention.
Read More »FDA Approves a Triple Therapy for Type 2 Diabetes in One Tablet
More may be better unless it involves tablets. A newly approved, more straightforward way to treat type 2 diabetes.
Read More »SGLT-2i Effects on Major Cardiovascular Events and Heart Failure
The use of SGLT2 inhibitors was associated with reduced risk of any cause of death in patients with or without a history of major cardiovascular disease.
Read More »Cost-effectiveness of Empagliflozin
Examining both the clinical and the cost outcomes for patients with type 2 diabetes with established cardiovascular disease.
Read More »Dapagliflozin and its Heart Failure Benefit
Could a newer diabetes medication provided clinicians with an alternative when managing heart failure?
Read More »Dapagliflozin vs. Saxagliptin: Durability of Glycemic Control
The persistence of benefits of dapagliflozin over saxagliptin might change therapy choices in patients with type 2 diabetes.
Read More »SGLT-2 Inhibitors’ Association with Fournier Gangrene
While rare, Fournier gangrene infections can worsen rapidly and have serious consequences.
Read More »Cardiovascular and Renal Benefits of SGLT2 Inhibitors
The use of SGLT-2 inhibitors produces cardiovascular benefits and reduces the risk of progression of renal impairment in patients with T2DM.
Read More »Little Known Benefit in Using SGLT2 Inhibitors
While the major impact of hypomagnesemia on cardiovascular outcomes and T2DM has been known, recent evidence suggests that SGLT2 inhibitors may normalize Mg2+ levels.
Read More »Canagliflozin’s Efficacy and Safety For Delaying and Possibly Preventing ESKD
Kidney failure is an enormous concern for people with T2D and DKD. This analysis confirms canagliflozin can slow its progression and have an impact on patients regardless of their level of kidney function.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.